<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03220074</url>
  </required_header>
  <id_info>
    <org_study_id>Si268/2017</org_study_id>
    <nct_id>NCT03220074</nct_id>
  </id_info>
  <brief_title>Linezolid for Treatment of Nontuberculous Mycobacterial Diseases</brief_title>
  <official_title>Efficacy and Tolerability of Linezolid for Treatment of Nontuberculous Mycobacterial Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Siam Pharmaceutical Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective open study to determine the efficacy and tolerability of oral linezolid
      600mg./day for the treatment of 50 patients with nontuberculous mycobacterial diseases will
      be conducted at Siriraj Hospital, Mahidol University, Bangkok, Thailand.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be an open label clinical study of oral linezolid combination with another oral
      antimycobacterial drug as the maintenance treatment of nontuberculous mycobacterial diseases
      in adult.

      The eligible patients will be treated and monitored for the efficacy and safety every 6 weeks
      until 6 months then every 3 months for a total duration of 18 months.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2017</start_date>
  <completion_date type="Anticipated">June 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open labelled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cure rate</measure>
    <time_frame>6 months</time_frame>
    <description>no symptom and sign of active infection without drug treatment for at least 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>rate of common adverse event (AE)</measure>
    <time_frame>18 months</time_frame>
    <description>rate of common AE of linezolid such as thrombocytopenia, optic neuritis and rate of treatment withdrawal due to AEs</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Non-tuberculous Mycobacterial Diseases</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>oral linezolid tablet 600 mg /day combine with either oral quinolone (ciprofloxacin or levofloxacin) or oral macrolide (azithromycin or clarithromycin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Tablet</intervention_name>
    <description>study drug given and monitored for efficacy and tolerability</description>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of non-tuberculous mycobacterial (NTM) diseases

          -  Active or stable diseases receiving either parenteral or oral antimycobacterial
             treatment

          -  Require at least more than 6 months of treatment from enrollment

        Exclusion Criteria:

          -  Stable NTM diseases with a plan to discontinue treatment within 3 months

          -  History of allergy to linezolid

          -  Hemoglobin &lt; 7 g/dl) or total white blood count &lt; 3,000 /cu.mm. or thrombocytopenia &lt;
             50,000 cells/cu.mm.

          -  Concomitant uses of serotoninergic drugs (SSRIs) or Monoamine oxidase inhibitor
             (MAOIs) within 30 days prior to enrollment

          -  Abnormal neurological findings such as numbness, abnormal vision etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yupin Suputtamongkol, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yupin Suputatmongkol, MD</last_name>
    <phone>66817545573</phone>
    <email>yupin.sup@mahidol.ac.th</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nasikarn Angkasekwinai, MD</last_name>
    <phone>66818708766</phone>
    <email>nasikarn@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkoknoi</city>
        <state>Bangkok</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yupin Suputtamongkol, MD</last_name>
      <phone>66 2 419 7203</phone>
      <email>yupin.sup@mahidol.ac.th</email>
    </contact>
    <contact_backup>
      <last_name>nasikarn Angkasekwinai, MD</last_name>
      <phone>66818708766</phone>
      <email>nasikarn@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Pakpoom Phoompoung, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Niphon Chirapapisan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suporn Foonglada, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peeraya Krongtip, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ekkarat Wongsawat, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2017</study_first_submitted>
  <study_first_submitted_qc>July 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2017</study_first_posted>
  <last_update_submitted>August 30, 2017</last_update_submitted>
  <last_update_submitted_qc>August 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Yupin Suputtamongkol</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycobacterium Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linezolid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

